2026-02-24
Testosterone Decline in Men: Natural Trajectory, Functional Impact, and Evidence-Based Support
Testosterone declines approximately 1-2% per year from age 30. The clinical significance of this decline depends on absolute levels and symptoms, not chronological age alone. Testosterone replacement therapy has RCT evidence for improving muscle mass, bone density, and sexual function in men with confirmed hypogonadism. Lifestyle factors significantly modify the trajectory.
2026-02-24
Cognitive Stress Reactivity: How Stress Disrupts Mental Performance and What to Do About It
Repeated psychological stress impairs working memory, attention, and decision-making through cortisol-mediated hippocampal effects. This article reviews the mechanisms and the evidence for stress-buffering interventions including adaptogens and behavioral strategies.
2026-02-24
Social Isolation and Loneliness in Aging: The Hidden Health Crisis
Loneliness and social isolation are among the strongest independent predictors of cardiovascular disease, cognitive decline, and early mortality in older adults. This article reviews the evidence and practical mitigation strategies.
2026-02-24
Testosterone Decline in Aging Men: Natural Interventions, Monitoring, and TRT Context
Testosterone declines ~1% per year after age 30 in men. Below clinical thresholds, symptoms include fatigue, sarcopenia, and cognitive fog. Lifestyle interventions (resistance training, sleep, zinc, vitamin D) have the best evidence for supporting endogenous production. Ashwagandha and fenugreek show modest RCT data.
2026-02-22
Longevity Protocol for Men Over 50: Evidence-Based Priorities
Men over 50 face accelerating cardiovascular, metabolic, and hormonal changes. This protocol covers the highest-leverage, evidence-based interventions for men in the second half of life.